At the European Patent Office, two recurring defaults lean on the same factual proposition: antibody generation and selection can be routine. Generative antibody design is about to make the limits of that proposition harder to ignore. The same efficiency that can make an antibody look obvious does not, by itself, make the breadth of a functional claim enabled.
Modern antibody-design pipelines can use generative models to propose large numbers of candidate sequences or structures, and computational models to rank or filter them before experimental testing. The output is a set of hypotheses about what may bind or perform a desired function, not a measurement that it does.
This article is about what this is changing at the European Patent Office (the EPO), where the same factual proposition, that antibody generation and selection can be routine, repeatedly helps the applicant under sufficiency and hurts it under inventive step. It asks what follows once routine candidate generation,